Photodynamic　therapy　(PDT)　was　hindered　by　the　poor　water　solubility　and　long-enduring　photoactivities　of　photosensitizers.　Here,　we　developed　a　novel　controllable　photodynamic　agent　CPHI　based　on　beta-cyclodextrin　modified　polyamidoamine　(PAMAM)　dendrimer　(CP)　co-delivery　of　indocyanine　green　(ICG)　and　hematoporphyrin　(HP).　The　CPHI　possessed　appropriate　particle　sizes　and　zeta　potentials,　considerable　photostability,　and　NIR-triggered　release　property.　The　fluorescence　of　HP　could　be　quenched　by　ICG　when　HP　and　ICG　were　co-loaded　inside　the　CP,　and　the　quenching　efficiency　was　related　with　the　weight　ratio　of　HP　and　ICG.　When　the　feeding　weight　proportion　of　HP　and　ICG　is　1/10,　the　fluorescence　of　HP　was　quenched　by　87.3%　in　CPHI.　Under　808　run　laser　irradiation,　the　ICG　in　CP　was　degraded,　and　the　fluorescence　of　HP　could　recover.　The　recovered　HP　was　capable　of　generating　reactive　oxygen　species　(ROS)　for　PDT　with　606　nm　laser　irradiation.　The　cytotoxicity　and　cell　apoptosis　studies　showed　that　CPHI　could　effectively　induce　MCF-7　cells　apoptosis　with　PDT　effects　under　808/660　run　laser.　These　results　suggested　that　CPHI　could　be　an　efficient　cancer　therapeutic　agent　for　controllable　PDT　with　low　dark　toxicity.